# US 11,896,601 B2 · Composition for prevention or treatment of allergic disease including inotodiol compound as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,601 B2
- Document ID: US11896601B2
- Status: Granted
- Kind: B2
- Application number: 17/050,878
- Filed: 2018-05-24
- Published: 2021-12-02
- Granted: 2024-02-13
- Earliest claimed: 2018-05-24
- Assignees: Carboexpert Inc.
- Applicants: Carboexpert Inc.
- Inventors: In Kyu Hwang; Young Ho Kim; Thi Minh Nguyet Nguyen; Jong Seong Kang
- Web page: https://patentgrep.com/patent/US11896601B2

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Provided is a composition for prevention or treatment of an allergic disease, the composition including an inotodiol compound and a chaga mushroom (Inonotus obliquus) extract including an inotodiol compound as an active ingredient. More particularly, it was found that when an inotodiol compound or a chaga mushroom extract containing an inotodiol compound as one of the active ingredients is administered to a mouse model in which a food allergy was induced, symptoms induced by the allergy were alleviated and cured. Thus, the inotodiol compound or the chaga mushroom extract containing an inotodiol compound as an active ingredient is expected to be useful as a composition for prevention or treatment of an allergic disease.

## Claims

### Claim 1

A method for preventing or treating an allergic disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a chaga mushroom (Inonotus obliquus) extract including an inotodiol compound represented by Formula 1 as an active ingredient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chaga mushroom extract is at least one selected from the group consisting of dichloromethane fractions or chloroform fractions obtained by adding dichloromethane or chloroform to an extract obtained by extracting chaga mushroom with 70 percent (%) ethanol as a solvent, respectively.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method suppresses degranulation of mast cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the allergic disease is induced by at least one selected from the group consisting of pollen, medicines, vegetable fibers, bacteria, food, dyes, and chemicals.

### Claim 5 (depends on 4)

The method of claim 4, wherein the allergic disease is induced by food.

### Claim 6 (depends on 1)

The method of claim 1, wherein the allergic disease is at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma, and atopic dermatitis.

### Claim 7

A method for preventing or treating an allergic disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of an inotodiol compound represented by Formula 1 as an active ingredient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the method suppresses degranulation of mast cells.

### Claim 9 (depends on 7)

The method of claim 7, wherein the allergic disease is induced by at least one selected from the group consisting of pollen, medicines, vegetable fibers, bacteria, food, dyes, and chemicals.

### Claim 10 (depends on 9)

The method of claim 9, wherein the allergic disease is induced by food.

### Claim 11 (depends on 7)

The method of claim 7, wherein the allergic disease is at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma, and atopic dermatitis.